<DOC>
	<DOCNO>NCT01382901</DOCNO>
	<brief_summary>The purpose study evaluate safety 2 dosage regimen Intravenous ( IV ) iron Ferric Carboxymaltose ( FCM ) comparison placebo patient Restless Legs Syndrome ( RLS )</brief_summary>
	<brief_title>Intravenous ( IV ) Iron Preparation ( VIT-45 ) Treatment Restless Legs Syndrome ( RLS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>Iron</mesh_term>
	<criteria>Male female subject &gt; = 18 year old , able give inform consent study . RLS sign symptom affirm diagnosis . The IRLS Diagnostic Criteria RLS must meet . Subjects RLS symptom &gt; = 5 night per week least past 3 month . A baseline score &gt; = 15 IRLS Rating Scale . At least one leg average baseline Periodic Leg Movement asleep ( PLMS ) &gt; = 15 movement per hour least 3 day baseline PLMS data measurable leg . Subjects antidepressant , sleep medication , dopamine agonist , benzodiazepine , narcotic RLS treatment must therapy least one week 5 half life , whichever long baseline RLS assessment PLM measurement obtain . Subject regular sleep hour 9 p.m. 9 a.m . Subjects risk pregnancy must negative pregnancy test baseline practice acceptable form birth control . RLS 2° CNS disease injury . Such disorder include peripheral neuropathy , neurodegenerative disorder , multiple sclerosis . RLS 2° Chronic Kidney Disease . Any pain related sleep relate disorder ( e.g . sleep apnea ) may confound outcome measure . History neuroleptic akathisia . Oral iron use ( include multivitamin iron ) screening . Parenteral iron use within 4 week prior screen . Parenteral iron use &gt; 125 mg per week within 4 8 week prior screen . History &gt; = 10 blood transfusion past 2 year . Anticipated need blood transfusion study . Known hypersensitivity reaction component FCM . Previously participate FCM clinical trial . Chronic serious active severe infection . Malignancy ( basal squamous cell skin cancer subject cancer free &gt; 5 year ) . Active inflammatory arthritis ( e.g . rheumatoid arthritis , SLE ) . Receiving prescription medication treatment bronchospasm . Pregnant lactating woman . Severe peripheral vascular disease significant skin change . Seizure disorder currently treat medication . Baseline ferritin &gt; 300 ng/mL . Baseline TSAT &gt; = 45 % . History hemochromatosis hemosiderosis iron storage disorder . AST ALT great upper limit normal . Hemoglobin great upper limit normal . Calcium phosphorous outside normal range . Known positive hepatitis B antigen ( HBsAg ) hepatitis C viral antibody ( HCV ) evidence active hepatitis . Known positive HIV1/HIV2 antibody ( antiHIV ) . Received investigational drug within 30 day randomization . Chronic alcohol drug abuse within past 6 month . Significant cardiovascular disease , include myocardial infarction within 12 month prior study inclusion , congestive heart failure NYHA ( New York Heart Association ) III IV , poorly control hypertension accord judgment investigator . Any preexist laboratory abnormality , medical condition disease view investigator participation study may put subject risk . Subject unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
</DOC>